Cargando…
Updates on cardiovascular outcome trials in diabetes
In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637292/ https://www.ncbi.nlm.nih.gov/pubmed/29020969 http://dx.doi.org/10.1186/s12933-017-0610-y |
_version_ | 1783270597751472128 |
---|---|
author | Schnell, Oliver Rydén, Lars Standl, Eberhard Ceriello, Antonio |
author_facet | Schnell, Oliver Rydén, Lars Standl, Eberhard Ceriello, Antonio |
author_sort | Schnell, Oliver |
collection | PubMed |
description | In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials confirmed cardiovascular safety for all tested anti-hyperglycaemic drugs and, in addition empagliflozin, semaglutide and liraglutide could even reduce cardiovascular risk. The present review summarizes the results of the DEVOTE, CANVAS, EXSCEL and ACE trials that tested cardiovascular safety of Insulin degludec, canagliflozin, once-weekly exenatide and acarbose and were published in 2017. We provide context on these results by comparing them with earlier trials of glucose-lowering drugs and give an outlook on what to expect in coming years. |
format | Online Article Text |
id | pubmed-5637292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56372922017-10-18 Updates on cardiovascular outcome trials in diabetes Schnell, Oliver Rydén, Lars Standl, Eberhard Ceriello, Antonio Cardiovasc Diabetol Review In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials confirmed cardiovascular safety for all tested anti-hyperglycaemic drugs and, in addition empagliflozin, semaglutide and liraglutide could even reduce cardiovascular risk. The present review summarizes the results of the DEVOTE, CANVAS, EXSCEL and ACE trials that tested cardiovascular safety of Insulin degludec, canagliflozin, once-weekly exenatide and acarbose and were published in 2017. We provide context on these results by comparing them with earlier trials of glucose-lowering drugs and give an outlook on what to expect in coming years. BioMed Central 2017-10-11 /pmc/articles/PMC5637292/ /pubmed/29020969 http://dx.doi.org/10.1186/s12933-017-0610-y Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Schnell, Oliver Rydén, Lars Standl, Eberhard Ceriello, Antonio Updates on cardiovascular outcome trials in diabetes |
title | Updates on cardiovascular outcome trials in diabetes |
title_full | Updates on cardiovascular outcome trials in diabetes |
title_fullStr | Updates on cardiovascular outcome trials in diabetes |
title_full_unstemmed | Updates on cardiovascular outcome trials in diabetes |
title_short | Updates on cardiovascular outcome trials in diabetes |
title_sort | updates on cardiovascular outcome trials in diabetes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637292/ https://www.ncbi.nlm.nih.gov/pubmed/29020969 http://dx.doi.org/10.1186/s12933-017-0610-y |
work_keys_str_mv | AT schnelloliver updatesoncardiovascularoutcometrialsindiabetes AT rydenlars updatesoncardiovascularoutcometrialsindiabetes AT standleberhard updatesoncardiovascularoutcometrialsindiabetes AT cerielloantonio updatesoncardiovascularoutcometrialsindiabetes AT updatesoncardiovascularoutcometrialsindiabetes |